Abstract: The present invention relates to a method of production and the use of a compositional ingredient. Specifically, the present invention relates to hydrosoluble stable organic salts of creatine and pyroglutamic acid. The compositional ingredient may be useful for the regulation of athletic and cognitive functions.

Abstract: The present invention provides novel intermediates represented by general formula (I) etc. for preparing a phenoxyacetic acid derivative represented by general formula (X) or a pharmaceutically acceptable salt thereof, which has ?3-adrenoceptor stimulating activity and are useful for treating or preventing obesity, hyperglycemia, diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression or biliary calculus. The present invention also provides a process for preparing said intermediates and a method of using said intermediates.

Abstract: A process for preparing 1,3-propanediol comprising the steps of: (a) preparing an aqueous mixture of 3-hydroxypropanal, (b) passing said aqueous 3-hydroxypropanal mixture to a hydrogenation zone wherein the hydrogenation zone is comprised of at least two stages wherein the hydrogenation in the first stage is carried out under hydrogenation conditions at a temperature in the range of about 50 to about 130° C. in the presence of a fixed bed or slurry hydrogenation catalyst and wherein an acidic co-catalyst is added or present in at least one of the later stages and the hydrogenation in said later stages is carried out under hydrogenation conditions at a higher temperature than that of the first hydrogenation stage and in the range of about 70 to about 155° C. to form an aqueous solution of 1,3-propanediol; and (c) recovering said 1,3-propanediol.

Abstract: The present invention relates to a process for preparing optionally substituted arylsulphonic anhydrides of the general formula (I)

Abstract: Disclosed is a method for enhancing absorption of a medicament that is suitable for administering transmucosally to a subject by providing an environment of the administration with a suitable pH. A medicament of propranolol suitably administered sublingually is provided. The medicament of propranolol can be used for treating diseases related to the cardiovascular system.

Abstract: Carboxylic acid ester is produced by esterification of carboxylic acid and an alcohol in a catalytic reaction zone of a first column at a pressure not greater than ambient pressure. The resultant sump product is distilled in a reaction zone of a second column at a pressure greater than 1.5 bar to obtain a second liquid sump product containing carboxylic acid ester with an carboxylic acid content of less than 100 ppm by weight at a lower end of the column. Neutralization of the second liquid sump product with a base is not required.

Abstract: A shell-and-tube type heat exchanger of the smallest possible length necessary for heat exchange is disclosed which is capable of obtaining uniform distribution of flow of a shell side fluid and substantially eliminating the structural restriction imposed on the shell side. This shell-and-tube type heat exchanger is provided with one annular conduit furnished with not less than two partitions concurrently serving as an expansion joint for introducing and discharging a shell side fluid and allowing the flow path for said shell side fluid to be separated into an introducing part and a discharging part and which comprises a place having no array of heat-transfer tubes in the flow path for said shell side fluid. It prevents the equipment from necessitating an unnecessary enlargement due to the structural restriction on the shell side and enables the shell side fluid to produce a uniform flow.

Abstract: The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions There are a variety of neurological disorders that can be treated using the present invention, including, for example, the following: neurological disorders arising from trauma, ischemic or hypoxic conditions that can be treated include stroke, hypoglycemia, cerebral ischemia, cardiac arrest, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest and hypoglycemic neuronal damage; neurodegenerative disorders such as epilepsy, Alzheimer's disease, Huntington's disease Parkinsonism, and amyotrophic lateral sclerosis; other diseases or disorders such as convulsion, pain, depression, anxiety, schizophrenia, muscle spasms, migraine headaches, urinary incontinence, nicotine withdrawal, opiate tolerance and withdrawal, emesis, brain edema

Abstract: Disclosed is a process for producing a benzylamine derivative represented by the general formula (3): wherein X1, R1 and R2 are as defined below, which comprises reacting a benzyl derivative represented by the general formula (1): wherein X1 represents a halogen atom and R1 represents an acyl group, with a haloacyl compound represented by the general formula (2): R2—X2??(2) wherein X2 represents a halogen atom and R2 represents an acyl group, in the presence of Lewis acid. According to this method, a benzylamine derivative as an intermediate, which is useful for the preparation of a carbamate-based agricultural or horticultural bactericide, can be preferably prepared.

Abstract: The present invention provides L-arginine salts of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these L-arginine salts of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of an inflammatory condition of the GI tract such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

Abstract: Provided is a novel triethyleneglycol based compound, a plasticizer composition for polyvinyl chloride resin including the same, and a method of preparing the plasticizer composition. In particular, the plasticizer composition for polyvinyl chloride resin includes the novel compound, 2-(2-(2-(2-ethylhexanoyloxy)ethoxy)ethoxy)ethyl 2-ethylhexanoate, and 2-(2-(2-phenylcarbonyloxyethoxy)ethoxy)ethyl benzoate in a proper mixture ratio. A polyvinyl chloride prepared using the plasticizer composition has low heating loss, excellent adhesion, high plasticization efficiency, high elongation, high tensile strength, and high transparency.

Abstract: Disclosed is an optimized system for more efficiently and economically producing terephthalic acid. A solvent purification system is employed to remove of at least one aromatic impurity present in a solvent purification feed. At least about 20 weight percent of the solvent purification feed originates from a cooled, post-digestion, TPA-containing slurry.

Abstract: The present invention provides a compound having one of the following formulae: R and R1 are each independently H or C1-5 alkyl provided that in formula (I) when R is methyl, R1 is H or C2-5 alkyl. R2 has from 1 to about 12 carbon atoms and is a straight or branched aliphatic group, or a cyclic, heterocyclic or aromatic group. R3 and R4 are each independently H or CH3. Mixtures of these compounds, methods for their preparation, their use as perfume materials for application to a variety of substrates and their use in flavoring and in articles of manufacture is also provided.

Abstract: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.

Abstract: A process for rectificatively separating a liquid which comprises acrylic acid, methacrylic acid or a mixture thereof, and additionally comprises low molecular weight aldehydes and acetone.

Abstract: A process for preparing xylylenediamine by continuously hydrogenating liquid phthalonitrile over a heterogeneous catalyst in the presence of liquid ammonia in a reactor, in which a portion of the reactor effluent is recycled as a liquid circulation stream continuously to the reactor inlet (circulation mode), in which a stream of a phthalonitrile melt in liquid form is conducted by means of a mixer unit into the circulation stream around the hydrogenation reactor, the phthalonitrile conversion in the reactor on single pass being greater than 99%, and the circulation stream consisting to an extent of greater than 93% by weight of liquid ammonia and xylylenediamine and not comprising any further solvent for phthalonitrile.

Abstract: Unsaturated alkyllysophosphonocholines compounds of formula (I) or (II): or pharmaceutically-acceptable salts, prodrugs or isomers thereof. The compounds of the invention have anti-neoplastic activity, and accordingly have utility in treating cancer and related diseases. The invention also provides enantiomers of these compounds, as well as synthetic methods for producing an enantiomer, substantially free of the other enantiomer. Also disclosed are pharmaceutical compositions, as well methods for treating cancer with the pharmaceutical compositions.

Abstract: The present invention is directed to labeled compounds of the formulae wherein Q is selected from the group consisting of —S—, —S(?O)—, and —S(?O)2—, Z is selected from the group consisting of 1-naphthyl, substituted 1-naphthyl, 2-naphthyl, substituted 2-naphthyl, and phenyl groups with the structure wherein R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, a C1-C4 lower alkyl, a halogen, and an amino group selected from the group consisting of NH2, NHR and NRR? where R and R? are each independently selected from the group consisting of a C1-C4 lower alkyl, an aryl, and an alkoxy group, and X is selected from the group consisting of hydrogen, a C1-C4 lower alkyl group, and a fully-deuterated C1-C4 lower alkyl group. The present invention is also directed to a process of preparing labeled compounds, e.g.

Abstract: Optically active diphenylalanine compounds may be conveniently prepared in a good yield by reacting a diphenylalanine compound represented by formula (1) with an optically active amine compound represented by formula (2) in the presence of an organic solvent to give a diastereomeric salt represented by formula (5) and then treating the diastereomeric salt under acidic conditions to give an optically active diphenylalanine compound represented by formula (3): wherein each symbol is as defined in the specification.

Abstract: The present invention is directed to a novel compound, its composition and use of a compound having a structural formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomers thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases